title: Exit of platelet glycoprotein-IIb/IIIa-receptor inhibitors?
authors.forename: P C
authors.initials: PC
authors.lastname: Adam
authors.forename: J
authors.initials: J
authors.lastname: Pemberton
authors.forename: K L
authors.initials: KL
authors.lastname: Evemy
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006406:Hematoma / Q000139:chemically induced*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012307:Risk Factors; D013300:Streptokinase / Q000008:administration & dosage / Q000009:adverse effects; D015912:Thrombolytic Therapy; D000077466:Tirofiban; D014443:Tyrosine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*
chemical_list: D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D013300:Streptokinase; D000077466:Tirofiban